CEO and Founder of Axiom Real-Time Metrics, Andrew Schachter, is featured in PharmaVOICE’s June 2019 edition for feature article “Data Ownership: Setting Up Your Study for Success”. ARTICLE EXERPT: A small-to medium-size biotech or medical device company typically succeeds or fails on one pivotal study. It cannot be underestimated how important the study and operational data are to the success …
Executive Viewpoints: The Evolving Impact of Patient-Centricity
CEO and Founder of Axiom Real-Time Metrics, Andrew Schachter, is featured in PharmaVOICE’s June 2017 edition’s “Executive Viewpoints” segment. ARTICLE EXCERPT: The Evolving Impact of Patient-Centricity The movement toward enabling the subject to be directly involved in various data streams such as diary and health-tracking information continues to evolve. For example, direct health activity data such as Fitbit information is …
Choosing the Right EDC/DM Partner: Critical Considerations for Small to Medium Sized Life Sciences Organizations
CEO and Founder of Axiom Real-Time Metrics, Andrew Schachter, is featured in PharmaVOICE’s June 2017 edition for feature article “Choosing the Right EDC/DM Partner: Critical Considerations for Small to Medium Sized Life Sciences Organizations”. ARTICLE EXCERPT: Whether you are a start-up pharmaceutical or biotech company, a medical devices innovator, or an established organization you want to be equipped with the …
Clinical Trials Yearbook: 5 Key Benefits to a Unified eClinical Suite
CEO and Founder of Axiom Real-Time Metrics, Andrew Schachter, is featured in the Clinical Trials Yearbook. ARTICLE EXCERPT: Keep calm and say no to the status quo: 5 Key Benefits to a Unified eClinical Suite Just as the iPad, Twitter and Smart Phones have changed how we communicate, access information, and generally move our knowledge forward, there are now enhanced …